<DOC>
	<DOCNO>NCT00830973</DOCNO>
	<brief_summary>This study assess impact CYP450 2D6 genotype pharmacogenetic test correspond prescribe impact postmenopausal woman use tamoxifen patient care set prevention recurrent breast cancer .</brief_summary>
	<brief_title>The Clinical Economic Impact Pharmacogenomic Testing Tamoxifen Metabolism Postmenopausal Women Receiving Tamoxifen Prevention Recurrent Breast Cancer</brief_title>
	<detailed_description>Tamoxifen non-steroidal hormonal drug weak estrogen agonist potent estrogen antagonist action . The liver CYP450 metabolic enzyme system responsible metabolize tamoxifen ( pro-drug form ) active metabolite . A secondary tamoxifen metabolite know specifically 4-hydroxy-N-desmethyl-tamoxifen endoxifen recognize principal potent metabolite responsible tamoxifen suppression estrogen-dependent cell proliferation , stimulus breast tumor growth . Biotransformation endoxifen CYPP450 2D6 pathway ; therefore , ability tamoxifen effectively suppress breast cancer jeopardize patient certain CYP450 2D6 genetic variant and/or receive drug therapy know alter CYP450 2D6 function ( i.e. , CYP450 2D6 inhibitor ) . Four phenotype expression classify ultrarapid , extensive , intermediate poor metabolizers discern genotype test CYP450 2D6 activity . Patients normal metabolic activity know extensive metabolizers give possess either two ( genotype = wt/wt ) one ( genotype = wt/vt ) function CYP450 2D6 gene convert sufficient amount tamoxifen active form . Intermediate metabolizers least low CYP450 2D6 activity appear uniform consensus impact phenotype tamoxifen drug disposition . Poor metabolizers lack functional CYP450 2D6 activity , therefore , metabolize tamoxifen enough produce sufficient endoxifen activity . Approximately 10 % patient ( 7 % Caucasians 1-3 % ethnic group ) poor metabolizers complete absence CYP450 2D6 activity . The genetic variant associate diminished absent CYP450 2D6 activity find CYP450 2D6 allele *3 , *4 , *5 , *6 *10 . The *3 , *4 , *5 *6 allele , present variant form ( genotype = vt/vt ) , account approximately 97 % nonfunctional CYP450 2D6 variant caucasian . Of mutation , CYP450 2D6 *4 significant endoxifen . Poor metabolizer phenotype associate bad relapse-free breast cancer survival increase risk ( three time intermediate metabolizer status CYP450 2D6 activity ) breast cancer recurrence . Diagnostic technology exist aid determine tamoxifen patient potentially receive suboptimal treatment exist alteration one approximately 80 allele gene cod CPYP450 2D6 enzyme . Recognition phenomenon provide physician patient opportunity consider use anti-estrogen drug aromatase inhibitor woman whose CYP450 2D6 phenotype put risk poor response tamoxifen therapy . This study use diagnostic technology determine patient 's phenotype provide additional clinical information alternative drug therapy patient 's physician .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Antineoplastic Agents , Hormonal</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<criteria>Patient currently pharmacy benefit Medco enrol client Patient adjudicate tamoxifen pharmacy claim within last six month Patient still take tamoxifen prevent recurrent breast cancer Patient natural postmenopausal woman 50 year age old Patient sign consent Patient willing provide sample genetic test Physician manage tamoxifen therapy willing order pharmacogenetic test Patient male Patient 50 year old Patient previous history CYP450 2D6 test Patient longer take tamoxifen Patient refuse sign consent Patient wish long participate test Patient 's physician refuse order pharmacogenetic test</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Estrogen Antagonists</keyword>
	<keyword>Antineoplastic Agents , Hormonal</keyword>
	<keyword>Hormone Antagonists</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormone Substitutes</keyword>
	<keyword>Selective Estrogen Receptor Modulators</keyword>
	<keyword>Estrogen Receptor Modulators</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
</DOC>